Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced plans to transition a significant portion of its IT infrastructure to Amazon Web Services (AWS), a move aimed at enhancing efficiency in drug discovery and clinical trial development. This multiyear initiative, revealed by parent company Amazon (NASDAQ: AMZN) this week, will be supported by professional services firm Accenture (NYSE: ACN).
By migrating to AWS, MSD anticipates a reduction in drug discovery timelines and an acceleration of clinical trial processes through the utilization of core applications, including systems applications and products (SAP), machine learning (ML), and data warehousing solutions.
This project builds upon a collaboration that began in 2021, which focused on optimizing MSD’s value chain. The partnership has already implemented AWS solutions to identify manufacturing defects, analyze inspection data, enhance computational capabilities for faster drug discovery, adjust resource allocation, and manage staff training effectively.- Flcube.com
